CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged

CorMedix reported second quarter results on August 13 showing substantial growth across major metrics. Net revenue reached $101.9 million, exceeding the prior year’s $39.7 million, while net income totaled $26 million and adjusted EBITDA climbed to $58.7 million compared with prior year figures. Management raised its full year adjusted EBITDA guidance while maintaining its full year revenue range at $325 million to $345 million, a decision that underscored cautious sentiment despite quart